Jijun Dong

Jijun Dong has a diverse and extensive work experience in the biotechnology and pharmaceutical industry. Jijun is currently serving as the Chief Scientific Officer at Salubris Biotherapeutics since May 2023. Prior to this, they held the position of Vice President Biologics at Xilio Therapeutics, Inc. starting from April 2022.

Before joining Xilio Therapeutics, Inc., Jijun Dong worked at Cygnal Therapeutics as the Executive Director from July 2021 to April 2022. Prior to that, they worked at Alkermes, where they held the roles of Sr. Director from December 2018 to July 2021 and Principal Scientist from April 2017 to December 2018. At Alkermes, they led a cross-functional project team focused on developing targeted immunotherapies for cancer treatment. Jijun played a crucial role in driving the discovery effort on biological target identification and led protein design and engineering to improve biological function and safety profiles.

Jijun Dong began their career at Novartis as an Investigator II from September 2013 to March 2017. Before that, they worked as an Investigator I from November 2010 to September 2013. During their time at Novartis, they specialized in developing and characterizing therapeutic antibodies and proteins for cardiovascular and metabolic diseases. Jijun also focused on identifying and characterizing targets for blood-brain barrier penetration.

Before joining the industry, Jijun Dong gained research experience as a Postdoctoral Fellow at Whitehead Institute from August 2006 to October 2010. Jijun started their career as a research assistant at Emory University from January 2000 to January 2006. Jijun also worked as a Chemist and research assistant at Peking University from January 1998 to January 2000.

Overall, Jijun Dong's work experience reflects their expertise in scientific research, leadership roles, and drug development across various organizations in the biotechnology and pharmaceutical industry.

Jijun Dong pursued a Bachelor of Science degree in Chemistry from Peking University between 1996 and 2000. Following this, they enrolled at Emory University from 2000 to 2006 where they obtained a Ph.D. in Biochemistry.